Exhibit 99.1 Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting Presented new data on the mechanisms of action of Calidi’s novel immunotherapies at the AACR Annual Meeting Unveiled RTNova systemic platform allowing for ease of administration and ability to target multiple tumor types Completed $6.1 million public offering SAN DIEGO—(BU ...